Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
migraine save search
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
Published: 2024-04-12 (Crawled : 13:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -1.92%
H: 0.0%
C: 0.0%
qulipta abbvie treatment for migraine
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Published: 2024-04-11 (Crawled : 23:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -1.01%
H: 2.04%
C: 1.17%
ajovy for teva trial migraine china results
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
Published: 2024-03-19 (Crawled : 21:00) - globenewswire.com
AEON | $4.66 -28.75% 2.58% 110K
|
|
| O: -4.03%
H: 7.45%
C: -8.9%
abp-450 fda update treatment biopharma meeting migraine
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada
Published: 2024-03-18 (Crawled : 13:00) - globenewswire.com
SCLX | $0.8812 -2.09% -2.13% 2.1M
|
|
| O: -0.73%
H: 3.31%
C: 0.74%
elyxyb drug patent company health approval review treatment canada migraine submission
FDA Decisions: CMC Issues Trip Up Satsuma in Nasal Migraine Drug Bid
Published: 2024-01-19 (Crawled : 14:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: -0.83%
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: 0.09%
H: 1.01%
C: 0.85%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.67%
H: 0.0%
C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.23%
H: 0.0%
C: 0.0%
fda drug migraine
Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada
Published: 2023-12-26 (Crawled : 16:00) - globenewswire.com
SCLX | $0.8812 -2.09% -2.13% 2.1M
|
|
| O: -1.43%
H: 20.29%
C: 17.39%
elyxyb drug company health approval treatment sciences canada neurological migraine submission
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
Published: 2023-12-18 (Crawled : 14:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.61%
H: 1.14%
C: 0.57%
europe commercialization migraine agreement
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine
Published: 2023-12-12 (Crawled : 13:00) - globenewswire.com
AEON | $4.66 -28.75% 2.58% 110K
|
|
| O: 2.62%
H: 3.02%
C: -7.35%
abp-450 treatment biopharma migraine study
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
Published: 2023-12-06 (Crawled : 10:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 0.1%
H: 1.09%
C: -2.38%
ajovy obesity migraine
Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs In Treating Acute Migraine Targeted By ELYXYB® with Potential Advantages Compared to Calcitonin Gene-Related Peptide (CGRP) Products and Triptan Therapy
Published: 2023-11-22 (Crawled : 14:00) - globenewswire.com
SCLX | $0.8812 -2.09% -2.13% 2.1M
|
|
| O: 2.52%
H: 8.08%
C: 3.96%
elyxyb company care research potential migraine therapy results market
A large international study of migraine reveals new biological pathways for treatment
Published: 2023-10-26 (Crawled : 18:00) - biospace.com/
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.24%
H: 0.71%
C: -0.66%
international treatment migraine study
Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs
Published: 2023-10-26 (Crawled : 11:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 1.39%
H: 0.63%
C: -0.83%
tnx-1900 pharmaceuticals migraine study
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
Published: 2023-10-19 (Crawled : 20:00) - globenewswire.com
AEON | $4.66 -28.75% 2.58% 110K
|
|
| O: 1.36%
H: 2.02%
C: -3.36%
abp-450 treatment biopharma topline trial migraine results phase 2
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
Published: 2023-10-17 (Crawled : 08:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.69%
H: 1.27%
C: -0.23%
ajovy depression teva migraine study
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
Published: 2023-09-19 (Crawled : 13:00) - prnewswire.com
PULM | $2.0 2.04% 2.0% 12K
|
Health Technology
|
| O: -0.56%
H: 5.54%
C: -0.35%
pur3100 fda treat application migraine
Tonix Pharmaceuticals Announces Commitment to Supply Tosymra® (sumatriptan Nasal Spray) 10 mg for Treatment of Acute Migraine to Meet Potential Increased Demand Following GSK’s Planned Discontinuation of Imitrex® (sumatriptan) Nasal Spray After January 2024
Published: 2023-09-06 (Crawled : 11:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 4.33%
H: 2.15%
C: -1.02%
tosymra treatment pharmaceuticals spray potential migraine
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
Published: 2023-08-24 (Crawled : 12:00) - globenewswire.com
AEON | $4.66 -28.75% 2.58% 110K
|
|
| O: 2.98%
H: 11.58%
C: 11.58%
patent treat biopharma migraine
AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults
Published: 2023-08-17 (Crawled : 06:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.87%
H: 0.49%
C: -0.75%
aquipta abbvie approval treatment migraine
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
Published: 2023-08-07 (Crawled : 12:20) - globenewswire.com
NXL | $1.44 -2.04% -2.08% 260K
|
|
| O: 6.67%
H: 0.0%
C: -7.0%
device technology migraine results study benefits
Click Therapeutics Launches Additional Randomized Clinical Study in Migraine, Conducted in Partnership with Syneos Health
Published: 2023-08-02 (Crawled : 14:20) - biospace.com/
SYNH | $42.98 0.0% 7.4M
|
Health Services
|
| O: 0.12%
H: 0.12%
C: -0.14%
partnership health therapeutics study
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.